Impact of HF etiology on the sustainability of favorable response after LVAD weaning: A VAD Wean Registry analysis
Abstract Background A subset of heart failure (HF) patients can experience significant improvement of their cardiac structure and function while on left ventricular assist device (LVAD) support. Purpose We sought to investigate the impact of HF etiology on the durability of cardiac improvement and favorable outcomes after LVAD weaning. Methods We studied 324 HF patients enrolled in the international multicenter VAD Wean Registry who received a durable continuous-flow LVAD and underwent device support weaning (Figure 1). Indications for VAD weaning included: structural/functional cardiac improvement meeting institutional criteria for "myocardial recovery" (responders) or LVAD-related complications accompanied by variable degrees of cardiac improvement (partial responders). Patients were divided into seven categories based on HF etiology: ischemic cardiomyopathy (CM) (n=30), post-myocarditis CM (n=65), peripartum CM (n=53), valvular CM (n=12), chemotherapy-induced CM (n=14) and idiopathic CM (n=150). The primary outcome was 2-year survival free of transplant or LVAD re-implantation. The secondary outcome was the LVEF, measured by echocardiography at 3, 6, 12 and 24 months post-LVAD weaning. Results Patients with idiopathic, peripartum and post-myocarditis CM had higher rate of 2-year survival free of transplant or LVAD re-implantation compared to patients with chemotherapy-induced CM (Figure 2-Panel A) (p-values: 0.009, 0.004, 0.001, respectively). Patients with post-myocarditis CM were also more likely to achieve the primary outcome compared to those with ischemic CM (ICM) (p-value, 0.009). The LVEF changes over time are depicted in the Figure 2-Panel B. Conclusions In this multicenter analysis the etiology of HF appears to impact the durability of favorable response after LVAD weaning. The degree of reverse remodeling achieved before VAD weaning and its impact on the durability of response in different HF etiologies warrants further investigation in studies with larger patient population and power.
Authors
- Stavros Drakos (ORCID: https://orcid.org/0000-0002-8626-7931)
- Omar Wever‐Pinzon (ORCID: https://orcid.org/0000-0002-2828-707X)
- Kevin Shah (ORCID: https://orcid.org/0000-0003-0896-2266)
- Ulrich P. Jorde (ORCID: https://orcid.org/0000-0002-9476-6466)
- Eleni Maneta (ORCID: https://orcid.org/0000-0001-5011-3036)
- Daniel Zimpfer (ORCID: https://orcid.org/0000-0002-2185-4895)
- Elizabeth Dranow (ORCID: https://orcid.org/0000-0002-5324-192X)
- Craig H. Selzman (ORCID: https://orcid.org/0000-0001-9218-4764)
- Sheela T. Patel (ORCID: https://orcid.org/0000-0001-5926-8173)
- Guy A. MacGowan (ORCID: https://orcid.org/0000-0002-2685-4165)
- Andrew Schwartzman
- Rebecca Cogswell (ORCID: https://orcid.org/0000-0001-5250-1198)
- Christos Kyriakopoulos (ORCID: https://orcid.org/0000-0001-8806-2561)
- James Schultz
- Stephan Schueler
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- Virginia Commonwealth University (US)
- University of Utah (US)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Maine Medical Center (US)
- University of Minnesota Medical Center (US)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Heart Journal
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1093/eurheartj/ehae666.1117
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00